Literature DB >> 24522482

The degree of asymptomatic hyperuricemia and the risk of gout. A retrospective analysis of a large cohort.

Hadar Duskin-Bitan1, Eytan Cohen, Elad Goldberg, Tzippy Shochat, Amos Levi, Moshe Garty, Ilan Krause.   

Abstract

This study was conducted to examine the relationship between the degree of asymptomatic hyperuricemia and the development of gout, in men and women. The database of a screening center was searched for all subjects with asymptomatic hyperuricemia (>7.0 mg/dl men, >5.6 mg/dl women) during 2000-2012. We included men and women without previous diagnosis of gout, and a follow-up of at least 5 years. The risk of gout was analyzed in relation to the degree of hyperuricemia at the first visit. Of the 5,234 subjects who matched the inclusion criteria, 4,241 were normouricemic at their first visit and 993 were hyperuricemic. The mean follow up period was 7.5 years. Gout was diagnosed at the last visit in 34 subjects; four in the normouricemia group and 30 in the hyperuricemia group (0.1 % vs. 3.0 %, p < 0.001). Only one woman developed gout. The odds ratio (OR) for developing gout was 32 times higher in the hyperuricemic group than in the normouricemic group. The OR to develop gout was 11.2 (confidence interval [CI] 3.6-35.2) in men with mild hyperuricemia compared to 107.1 (CI 34.2-334.9) in men with moderate hyperuricemia, and 624.8 (CI 134.0-2,913.1) in men with severe hyperuricemia. Multivariate analysis of uric acid levels, thiazide use, regular alcohol consumption and estimated glomerular filtration rate (eGFR) showed that only the level of uric acid retained statistically significant for increasing the risk of gout. There is a strong association between the absolute level of uric acid and the risk to develop gout, strikingly so for men with severe hyperuricemia. Monitoring is recommended for that group, which poses the greatest risk to develop gout.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24522482     DOI: 10.1007/s10067-014-2520-7

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  23 in total

1.  [Hypersensitivity syndrome during therapy with allopurinol in asymptomatic hyperuricemia with a fatal outcome].

Authors:  B Hammer; A Link; A Wagner; M Böhm
Journal:  Dtsch Med Wochenschr       Date:  2001-11-23       Impact factor: 0.628

2.  2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis.

Authors:  Dinesh Khanna; Puja P Khanna; John D Fitzgerald; Manjit K Singh; Sangmee Bae; Tuhina Neogi; Michael H Pillinger; Joan Merill; Susan Lee; Shraddha Prakash; Marian Kaldas; Maneesh Gogia; Fernando Perez-Ruiz; Will Taylor; Frédéric Lioté; Hyon Choi; Jasvinder A Singh; Nicola Dalbeth; Sanford Kaplan; Vandana Niyyar; Danielle Jones; Steven A Yarows; Blake Roessler; Gail Kerr; Charles King; Gerald Levy; Daniel E Furst; N Lawrence Edwards; Brian Mandell; H Ralph Schumacher; Mark Robbins; Neil Wenger; Robert Terkeltaub
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-10       Impact factor: 4.794

3.  Female gout. Clinical spectrum and uric acid metabolism.

Authors:  J G Puig; A D Michán; M L Jiménez; C Pérez de Ayala; F A Mateos; C F Capitán; E de Miguel; J B Gijón
Journal:  Arch Intern Med       Date:  1991-04

4.  Hyperuricemia and metabolic syndrome: lessons from a large cohort from Israel.

Authors:  Eytan Cohen; Ilan Krause; Abigail Fraser; Elad Goldberg; Moshe Garty
Journal:  Isr Med Assoc J       Date:  2012-11       Impact factor: 0.892

5.  Moderate-to-severe early-onset hyperuricaemia: a prognostic marker of long-term kidney transplant outcome.

Authors:  Sang Il Min; Ik Jin Yun; Jin Mo Kang; Yang Jin Park; Seung Kee Min; Curie Ahn; Sang Joon Kim; Jongwon Ha
Journal:  Nephrol Dial Transplant       Date:  2009-04-25       Impact factor: 5.992

6.  Dietary and lifestyle changes associated with high prevalence of hyperuricemia and gout in the Shandong coastal cities of Eastern China.

Authors:  Zhimin Miao; Changgui Li; Ying Chen; Shihua Zhao; Yangang Wang; Zhongchao Wang; Xinyan Chen; Feng Xu; Fang Wang; Ruixia Sun; Jianxia Hu; Wei Song; Shengli Yan; Cong-Yi Wang
Journal:  J Rheumatol       Date:  2008-07-15       Impact factor: 4.666

7.  The clinical spectrum of gouty arthritis in women.

Authors:  E V Lally; G Ho; S R Kaplan
Journal:  Arch Intern Med       Date:  1986-11

8.  Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study.

Authors:  E W Campion; R J Glynn; L O DeLabry
Journal:  Am J Med       Date:  1987-03       Impact factor: 4.965

9.  Is thiazide-produced uric acid elevation harmful? Analysis of data from the Hypertension Detection and Follow-up Program.

Authors:  H G Langford; M D Blaufox; N O Borhani; J D Curb; A Molteni; K A Schneider; S Pressel
Journal:  Arch Intern Med       Date:  1987-04

10.  Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000-2005.

Authors:  L Annemans; E Spaepen; M Gaskin; M Bonnemaire; V Malier; T Gilbert; G Nuki
Journal:  Ann Rheum Dis       Date:  2007-11-02       Impact factor: 19.103

View more
  11 in total

Review 1.  Global epidemiology of gout: prevalence, incidence and risk factors.

Authors:  Chang-Fu Kuo; Matthew J Grainge; Weiya Zhang; Michael Doherty
Journal:  Nat Rev Rheumatol       Date:  2015-07-07       Impact factor: 20.543

Review 2.  An old disease with new insights: Update on diagnosis and treatment of gout.

Authors:  Berivan Bitik; M Akif Öztürk
Journal:  Eur J Rheumatol       Date:  2014-06-01

Review 3.  The effect of angiotensin II receptor blockers on hyperuricemia.

Authors:  Marissa L Wolff; Jennifer L Cruz; Adam J Vanderman; Jamie N Brown
Journal:  Ther Adv Chronic Dis       Date:  2015-11       Impact factor: 5.091

Review 4.  Comparative efficacy and safety of urate-lowering therapy for the treatment of hyperuricemia: a systematic review and network meta-analysis.

Authors:  Shu Li; Hongxi Yang; Yanan Guo; Fengjiang Wei; Xilin Yang; Daiqing Li; Mingzhen Li; Weili Xu; Weidong Li; Li Sun; Ying Gao; Yaogang Wang
Journal:  Sci Rep       Date:  2016-09-08       Impact factor: 4.379

5.  The risk of clinically diagnosed gout by serum urate levels: results from 30 years follow-up of the Malmö Preventive Project cohort in southern Sweden.

Authors:  Meliha C Kapetanovic; Peter Nilsson; Carl Turesson; Martin Englund; Nicola Dalbeth; Lennart Jacobsson
Journal:  Arthritis Res Ther       Date:  2018-08-29       Impact factor: 5.156

6.  Knowledge and practice in the management of asymptomatic hyperuricemia among primary health care physicians in Jeddah, Western Region of Saudi Arabia.

Authors:  Norah A Alqarni; Abdul H Hassan
Journal:  Saudi Med J       Date:  2018-12       Impact factor: 1.484

7.  The Different Relationship between Homocysteine and Uric Acid Levels with Respect to the MTHFR C677T Polymorphism According to Gender in Patients with Cognitive Impairment.

Authors:  Hee-Jin Kim; Il Woong Sohn; Young Seo Kim; Jae-Bum Jun
Journal:  Nutrients       Date:  2020-04-19       Impact factor: 5.717

8.  Dietary Interventions for Gout and Effect on Cardiovascular Risk Factors: A Systematic Review.

Authors:  Daisy Vedder; Wendy Walrabenstein; Maaike Heslinga; Ralph de Vries; Michael Nurmohamed; Dirkjan van Schaardenburg; Martijn Gerritsen
Journal:  Nutrients       Date:  2019-12-04       Impact factor: 5.717

9.  Incidence and Risk Factors of Hyperuricemia among 2.5 Million Chinese Adults during the Years 2017-2018.

Authors:  Ruiqi Shan; Yi Ning; Yuan Ma; Xiang Gao; Zechen Zhou; Cheng Jin; Jing Wu; Jun Lv; Liming Li
Journal:  Int J Environ Res Public Health       Date:  2021-02-28       Impact factor: 3.390

10.  Characteristics of the first metatarsophalangeal joint in gout and asymptomatic hyperuricaemia: a cross-sectional observational study.

Authors:  Sarah Stewart; Nicola Dalbeth; Alain C Vandal; Keith Rome
Journal:  J Foot Ankle Res       Date:  2015-08-18       Impact factor: 2.303

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.